Please login to the form below

Not currently logged in
Email:
Password:

Double chin

This page shows the latest Double chin news and features for those working in and with pharma, biotech and healthcare.

Allergan adds Zeltiq to M&A roster in $2.48n deal

Allergan adds Zeltiq to M&A roster in $2.48n deal

Other deals in the aesthetics sector include Allergan's $2.1bn purchase of Kythera in 2015, bringing in double chin-reducing therapy Kybella (deoxycholic acid), and the takeover of regenerative medicine

Latest news

  • Rare disease therapies head the ‘class of 2015’ Rare disease therapies head the ‘class of 2015’

    Kythera Biopharma created a new therapeutic category in the pharma/cosmetic area with Kybella (deoxycholic acid), the first drug for reducing double chin, while Sprout Pharma chalked up the first approval ... Kybella. submental contouring (double chin).

  • Allergan inks $2.1bn deal to buy cosmetic drug firm Kythera Allergan inks $2.1bn deal to buy cosmetic drug firm Kythera

    Allergan inks $2.1bn deal to buy cosmetic drug firm Kythera. Company will add Kythera’ s double chin therapy Kybella to its portfolio. ... Botox manufacturer Allergan has extended its position in the growing cosmetic or 'aesthetic' pharmaceuticals

  • Kythera bags FDA approval for double chin therapy Kythera bags FDA approval for double chin therapy

    Kythera bags FDA approval for double chin therapy. Comes as cosmetics industry sees major growth. ... The US FDA has approved the first drug to treat submental fat in adults - otherwise known as a double chin.

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Pharma deals in June 2015 Pharma deals in June 2015

    fat (double chin). ... Kythera Biopharmaceuticals/ Allergan. Rx aesthetic medicine products - incl Kybella for double chin (FDA approved).

  • Pharma deals during March 2014 Pharma deals during March 2014

    In addition, Five Prime could receive up to $300m in future development, regulatory and sales-based milestones per collaboration target, as well as tiered mid-single-digit rising to ... ATX-101 is a proprietary injectable formulation of a synthetic

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics